Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance
Drug Design, Development and Therapy · 2026-04 · Volume 20 · 1-18
DOI: 10.2147/dddt.s576169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-04. Verfasst von Sarfaraz K Niazi. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Drug Substitution, Recombinant Proteins, Biological Products. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, USA.
ORCID-Profile: Sarfaraz K Niazi
Zitieren
APA
Niazi, S. K. (2026). Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance. Drug Design, Development and Therapy, Volume 20, 1-18. https://doi.org/10.2147/dddt.s576169
Vancouver
Niazi SK. Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance. Drug Design, Development and Therapy. 2026;Volume 20:1-18. doi:10.2147/dddt.s576169
BibTeX
@article{Niazi2026,
author = {Niazi, Sarfaraz K},
title = {Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--18},
doi = {10.2147/dddt.s576169}
}
EUVIMED